Fundraising Fox
/Companies
Sign in

SolasCure

1 known investors

Find your way into SolasCure

Sign up to see every warm intro you have to SolasCure

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the SolasCure team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

SolasCure is developing mechanism-driven therapeutics to address biological barriers in chronic wound healing, with its lead candidate Aurase Wound Gel completing Phase II clinical trials. The company serves clinicians and healthcare systems seeking clinically validated approaches to improve outcomes for patients with non-healing or slowly healing wounds.

BiotechHealthtechMedical Devices

Founders & leadership

LHLee Harle
Lee HarleChief Executive OfficerLee Harle is Chief Executive Officer at SolasCure and previously founded or co-founded Alkamis (a venture builder and advisory firm focused on life science ventures), Sciopolis (a lab space provider for science and technology companies in partnership with Imperial College), Polypharmakos (a joint venture between Royal Botanic Gardens Kew and the University of Cambridge focused on natural products for human health), and served as a founding team member at Holos LifeSciences.
DB
Dr. Bela KeletyChief Technology Officer

Board

AWAndy Weymann
Andy WeymannChairmanVenture Partner, Frontiers in Health & Bio Investments at Verve Ventures

Investors · 1

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does SolasCure do?
SolasCure is developing mechanism-driven therapeutics to address biological barriers in chronic wound healing, with its lead candidate Aurase Wound Gel completing Phase II clinical trials. The company serves clinicians and healthcare systems seeking clinically validated approaches to improve outcomes for patients with non-healing or slowly healing wounds.
Who are SolasCure's investors?
SolasCure's investors include Seneca Partners.